Latest news

• TMC preps filings for inclisiran after final phase 3 trials hit the mark

  The ORION-9 and ORION-10 data will be reported in full at the American Heart Association (AHA) meeting in November.

• AZ says target of $45bn sales by 2023 still achievable

  The product has new cardiovascular outcomes data from the DECLARE-TIMI 58 trial – a must-have for diabetes therapies now – which is due for presentation at the American Heart Association (AHA) ... It will be followed by additional studies in patients

• Amgen's Repatha unclogs blocked arteries, says study

  At the American Heart Association (AHA) annual meeting this week, lead study author Stephen Nichols of the University of Adelaide in Australia reported that adding a monthly Repatha shot to daily ... The results have also been published in the Journal of

• Sanofi plans 18 new product launches by 2020

  These include cholesterol-lowering antibody alirocumab (now given the proposed trade name of Praluent) - fresh from encouraging new data presented at the American Heart Association meeting - as well a vaccine against ... the company will be keen to

• PCSK9 inhibitor alirocumab works in statin-intolerance

  Sanofi and Regeneron’s drug impresses at American Heart Association meeting. Sanofi and Regeneron's investigational drug alirocumab is more effective at reducing cholesterol levels than Merck &Co's Zetia in ... The ODYSSEY ALTERNATIVE trial - reported